Effect of early radiotherapy combined with androgen deprivation therapy after radical prostatectomy on local control and survival in patients with high-risk prostate cancer

doi:10.3969/j.issn.1006-7795.2016.03.012

Abstract

Abstract: Objective To investigate the effect of radiotherapy combined with androgen deprivation therapy after radical prostatectomy on local control and survival in patients with high-risk prostate cancer.Methods Fourteen patients with high-risk prostate cancer seen from 2010 to 2015 were treated with three dimension-conformal radiotherapy (3D-CRT) or intensive modulation radiotherapy (IMRT) combined with androgen deprivation therapy after radical prostatectomy. The basic information, surgery, radiotherapy complications, prostate specific antigen (PSA) after surgery and survival condition of the patients were collected.Results Mean follow-up period was 20 (2-52) months. During radiotherapy, no severe complications occurred in the fourteen treated patients, 5 patients had mild frequent or urgent urination, 2 patients had mild diarrhea and abdominal distension, and only 1 patient had transient reduced leucocyte count without abnormal hemoglobin and platelet. PSA increased to 6 ng/mL from 0.056 ng/mL after radiotherapy without local recurrence and metastasis in one patient who resumed taking androgen deprivation therapy (bicalutamide and leuprorelin) for 5 months and PSA decreased to 1.539 ng/mL. The other 13 patients survived without biochemical and local recurrence.Conclusion Early adjuvant radiotherapy combined with androgen deprivation therapy after radical prostatectomy improve the local control and survival in the patients of high-risk prostate cancer.

Key words: high-risk prostatic cancer, radical prostatectomy, radiotherapy, androgen deprivation therapy

CLC Number:

R737.25

Jin Song, Zhang Tian, Zheng Yingjie, Song Liming, Ping Hao, Wasilijiang·wahafu, Niu Yinong, Xing Nianzeng. Effect of early radiotherapy combined with androgen deprivation therapy after radical prostatectomy on local control and survival in patients with high-risk prostate cancer[J]. Journal of Capital Medical University, 2016, 37(3): 318-322.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.03.012

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I3/318

References

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015,65(1): 5-29.
[2] 韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013,18(4): 330-334.
[3] NCCN. The NCCN prostate cancer clinical practice guidelines in oncology (version 2.2016)[EB/OL]. Fort Washington: NCCN,2016[2016-03-13]. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pd
[4] Stephenson A J, Scardino P T, Eastham J A, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy[J]. J Am Soc Clin Oncol, 2005, 23(28): 715-717.
[5] Swindle P, Eastham J M, Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens[J]. J Urol, 2005, 179(Suppl 5): 47-51.
[6] Kupelian P A, Katcher J, Levin H S, et al. State T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy?[J]. Int J Radiat Oncol Biol Phy, 1997,37(5): 1043-1052.
[7] Mottet N, Bellmunt J, Bolla M, et al. European agyssociation of Urology Guidelines-2015[U]. European Association Urology, 2015: 25-27.
[8] Thompson I M, Valicenti R K, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline[J]. J Urol, 2013,190(2): 441-449.
[9] 那彦群,叶章群, 中国泌尿外科疾病诊断治疗指南手册[M]. 北京:人民卫生出版社,2014: 61-89.
[10] Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2012, 380(9858): 2018-2027.
[11] Thompson I M, Tangen C M, Jorge P, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial[J]. JAMA, 2006, 296(19): 2329-2335.
[12] Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95[J]. J Clin Oncol, 2009, 27(18): 2924-2930.
[13] van der Poel H G, Tillier C, de Blok W, et al. Salvage radiotherapy after robot-assisted laparoscopic radical prostatectomy[J]. Urology, 2013, 82(4): 834-839.
[14] Ohri N, Dicker A P, Trabulsi E J, et al. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling[J]. Eur J Cancer, 2012, 48(6): 837-844.
[15] Geinitz H, Riegel M G, Thamm R, et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy[J]. Int J Radiat Oncol Biol Phys, 2012,82(5): 1930-1937.
[16] Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy What is the best time to treat?[J]. Radiothe Oncol, 2012, 103(2): 239-243.
[17] Choo R, Danjoux C, Gardner S, et al. Efficacy of salvage radiotherapy plus 2-Year androgen suppression for postradical prostatectomy patients with PSA relapse[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4): 983-989.
[18] Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review[J]. Int J Radiat Oncol Biol Phys, 2008, 72(4): 972-979.
[19] Bolla M, Poppel H V, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2005, 366(9485): 572-578.
[20] Thompson I M, Tangen C M, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-Term followup of a randomized clinical trial[J]. J Urol, 2009, 181(3): 956-962.
[21] Dorff T B, Flaig T W, Tangen C M, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 Study[J]. J Clin Oncol, 2011, 29(15): 2040-2045.